factor viii fviii essential bloodclotting protein also known antihemophilic factor ahf humans factor viii encoded defects gene result hemophilia xlinked coagulation factor viii produced liver sinusoidal cells endothelial cells outside liver throughout body protein circulates bloodstream inactive form bound another molecule called von willebrand factor injury damages blood vessels response injury coagulation factor viii activated separates von willebrand factor active protein sometimes written coagulation factor viiia interacts another coagulation factor called factor ix interaction sets chain additional chemical reactions form blood factor viii participates blood coagulation cofactor factor ixa presence phospholipids forms complex converts factor x activated form xa factor viii gene produces two alternatively spliced transcripts transcript variant encodes large glycoprotein isoform circulates plasma associates von willebrand factor noncovalent complex protein undergoes multiple cleavage events transcript variant encodes putative small protein isoform b consists primarily phospholipid binding domain factor viiic binding domain essential coagulant people high levels factor viii increased risk deep vein thrombosis pulmonary copper required cofactor factor viii copper deficiency known increase activity factor formulation medication model list essential medicines important medications needed basic health factor viii first characterized scientists gene factor viii located x chromosome gene factor viii presents interesting primary structure another gene embedded one factor viii protein consists six domains homologous factor v domains homologous domains copperbinding protein c domains belong phospholipidbinding discoidin domain family domain mediate membrane activation factor viii factor viiia done cleavage release b domain protein divided heavy chain consisting domains light chain consisting domains form noncovalently complex calciumdependent manner complex procoagulant factor fviii glycoprotein procofactor although primary site release humans ambiguous synthesized released bloodstream vascular glomerular tubular endothelium sinusoidal cells hemophilia corrected liver transplanting hepatocytes ineffective liver endothelial cells blood mainly circulates stable noncovalent complex von willebrand factor upon activation thrombin factor iia dissociates complex interact factor ixa coagulation cascade cofactor factor ixa activation factor x turn cofactor factor va activates thrombin thrombin cleaves fibrinogen fibrin polymerizes crosslinks using factor xiii blood clot factor viii protein halflife hours blood stream stabilized von willebrand factor longer protected vwf activated fviii proteolytically inactivated process prominently activated protein c factor ixa quickly cleared blood stream factor viii affected liver disease fact levels usually elevated fviii concentrated donated blood plasma alternatively recombinant fviia given hemophiliacs restore hemostasis antibody formation factor viii also major concern patients receiving therapy bleeding incidence inhibitors dependent various factors including factor viii product factor viii related antigen used target immunohistochemistry endothelial cells megakaryocytes platelets mast cells normally stain pharmaceutical companies baxter international bayer sparked controversy continuing sell contaminated factor viii new heattreated versions fda pressure unheated product pulled us markets sold asian latin american european countries product tainted hiv concern discussed bayer us food drug administration early pharmaceutical companies began produce recombinant synthesized factor products prevent nearly forms disease transmission replacement therapy factor viii first discovered purification edward tuddenham frances rotblat coworkers led molecular identification crystal structure domain human factor viii resolution human factor viii domain complexed human monoclonal fab httpsenwikipediaorgwikifactorviii